Drug intelligence / Profile preview

SARS-CoV-2 mRNA Vaccine, Bivalent

Development stage: Phase 1
Lead developer: AIM Vaccine Co.
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SARS-CoV-2 mRNA Vaccine, Bivalent is an mRNA-based vaccine developed by AIM Vaccine Co., Ltd. and Ningbo Rong'an Biological Pharmaceutical Co., Ltd. for the prevention of Novel Coronavirus Pneumonia (COVID-19). As a bivalent vaccine, it is designed to elicit a broad immune response by presenting genetic material corresponding to the spike proteins of two different SARS-CoV-2 strains.

Other names: COVID-19 mRNA Vaccine, Bivalent

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SARS-CoV-2 mRNA Vaccine, Bivalent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 mRNA Vaccine, Bivalent.

Explore the full profile